$AND News
Last published 2mo ago
- 2mo agoTEVAANDTeva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth StrategyGlobeNewswireBXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
- 4mo agoTEVAANDTeva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisBusiness WireTeva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot
- 4mo agoTEVAANDTeva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisGlobeNewswireTeva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to
- 5mo agoANDMedincell: The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in AdultsBusiness WireThe olanzapine long-acting injectable (TEV-'749 / mdc-TJK) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks. If approved, TEV-‘749 could help fill a
- 5mo agoTEVAANDThe European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-'749) for the Treatment of Schizophrenia in AdultsGlobeNewswireThe olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet
- 11mo agoTEVAANDTeva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®GlobeNewswireFollowing the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to
- 1y agoTEVAANDTeva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in EuropeGlobeNewswireTeva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing
- 1y agoTEVAANDTeva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in IsraelGlobeNewswireKlinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful collaboration of
- 1y agoTEVAANDSamsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United StatesGlobeNewswireMarks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S.Partnership
- 2y agoTEVAANDTeva Statement on European Commission Decision; Company to AppealGlobeNewswireTeva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupportedThe company intends to appeal the outcome
- 5y agoTEVAANDTeva and Bioeq Announce Commercial Partnership for BiosimilarBusiness WireAgreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets Teva Pharmaceutical Industries Ltd. (NYSE:AND) and Bioeq AG ("Bioeq") today announced that they have e
- 6y agoandStatement in Response to News of the Indictment of Teva USABusiness WireTEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Today Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) is responding to news reports detailing that a federal grand jury in Philadelphia, Pennsylvania has returned a criminal indictment charging Teva USA with three counts of antitrust violations under the Sherman Act.
- 6y agoandTeva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar MarketBusiness WireTEL AVIV, Israel & REYKJAVIK, Iceland--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. This strategic partnership combines Teva’s long-standing commercial presence and extensive ...